FTY720 (Fingolimod) Sensitizes Prostate Cancer Cells to Radiotherapy by Inhibition of Sphingosine Kinase-1

Dmitri Pshezhetsky1,4,5, Torsten Bohler2, Leyre Brizuela4, Lysann Sauer1, Nicolas Doumerc3, Muriel Golzio4,5, Vishal Salunkhe1, Justin Teissié4,5, Bernard Malavaud3,4,5, Jonathan Waxman1, and Olivier Cuvillier3,4,5

Abstract

Radiotherapy is widely used as a radical treatment for prostate cancer, but curative treatments are elusive for poorly differentiated tumors where survival is just 15% at 15 years. Dose escalation improves local response rates but is limited by tolerance in normal tissues. A sphingosine analogue, FTY720 (fingolimod), a drug currently in phase III studies for treatment of multiple sclerosis, has been found to be a potent apoptosis inducer in prostate cancer cells. Using in vitro and in vivo approaches, we analyzed the impact of FTY720 on sphingolipid metabolism in hormone-refractory metastatic prostate cancer cells and evaluated its potential as a radiosensitizer on cell lines and prostate tumor xenografts. In prostate cancer cell lines, FTY720 acted as a sphingosine kinase 1 (SphK1) inhibitor that induced prostate cancer cell apoptosis in a manner independent of sphingosine-1-phosphate receptors. In contrast, γ irradiation did not affect SphK1 activity in prostate cancer cells yet synergized with FTY720 to inhibit SphK1. In mice bearing orthotopic or s.c. prostate cancer tumors, we show that FTY720 dramatically increased radiotherapeutic sensitivity, reducing tumor growth and metastasis without toxic side effects. Our findings suggest that low, well-tolerated doses of FTY720 could offer significant improvement to the clinical treatment of prostate cancer.

Introduction

In the western world prostate cancer is now the most commonly diagnosed noncutaneous cancer in men and is the second leading cause of cancer-related death (1). In the United States the lifetime probability of developing prostate cancer is 1 in 6, and it is estimated that 192,280 new cases of prostate cancer were diagnosed during 2009, and there were 27,360 deaths.

The management of prostate cancer is complex, but for the majority of patients radiotherapy remains a definitive treatment for early-stage disease. However, up to 85% of patients with poor histologic subtypes of localized prostate cancer relapse (2). In radiotherapy research the current emphasis is on computerized planning to deliver increased dosage schedules. There is an opportunity to approach the subject of dose intensification from a different angle, and this is through the use of radiosensitizer treatment.

Prostate cancer cell radioresistance has been linked with sustained activation of sphingosine kinase-1 (SphK1; ref. 3). SphK1 is a lipid converting enzyme responsible for the conversion of sphingosine into sphingosine-1-phosphate (S1P). S1P, and sphingosine and its precursor ceramide are lipid second messengers. In response to various stimuli ceramide and sphingosine mediate cell death, whereas S1P abrogates apoptosis and mediates cell proliferation and migration (4).

The SphK1/S1P pathway contributes to cancer progression and leads to increased cell proliferation (5), impairment of apoptosis (6), and oncogenic transformation (7). SphK1 is a tumor-associated enzyme: high levels of SphK1 expression have been shown in various human tumor tissues (8, 9). Furthermore high levels of SphK1 expression and activity are associated with a poor prognosis in breast cancer (10), glioma (11), and gastric cancer (12).

These findings have highlighted the potential of SphK1 as a therapy target. A sphingosine analogue, dimethylsphingosine, was the first reported SphK inhibitor to induce prostate cancer cell apoptosis (3). These findings were further confirmed by ourselves (13), showing a new selective SphK inhibitor, SKI-II (first reported by French et al.; ref. 9), to have proapoptotic properties in prostate cancer cells. Work from our group in prostate cancer indicates that inhibition of the SphK1/S1P pathway has a synergistic effect with chemotherapy and has the potential to act as a molecular target for cancer therapy (14–16).

FTY720 is a sphingosine analogue and a potent immunosuppressive drug that induces lymphopenia via an inhibition...
of lymphocytes' egress from lymphoid organs through its antagonist function on the lymphocytes' S1P receptors (17, 18). Recently the results of phase III trials have become available, showing significant potential of oral FTC720 (fingolimod) in multiple sclerosis patients (19, 20).

Surprisingly, at higher doses FTC720 has been shown to be a potent apoptosis inducer in prostate, liver, and bladder cancer cell lines (21–23). In a mouse model of melanoma FTC720 inhibited tumor growth and metastasis (24) without causing detectable toxicity in vital organs. Direct mitochondria damage (25), activation of caspases (21), and dephosphorylation of Akt (26) have all been proposed as potential mechanisms for FTC720-induced apoptosis. The effects of FTC720 were reported to be both S1P receptor dependent (24) and independent (27). In prostate cancer cells FTC720 has been shown to be a potent apoptosis inducer (21), whereas normal prostate cells exhibited resistance to the drug. FTC720 has been shown to inhibit prostate cancer cell invasion via downregulation of GTP-bound active form of RhoA (28), and administration of FTC720 at 10 mg/kg/day reduced the growth of prostate CWR22R xenografts in castrated nude mice (29).

In this current study we identified a novel mechanism of FTC720-induced prostate cancer cell apoptosis. Here we report that FTC720 can act as a SphK1 inhibitor in vitro and in vivo and that SphK1 inhibition is critical for FTC720-induced apoptosis. Sublethal concentrations of FTC720 act as radiosensitizer in cell lines and in implanted tumors, reducing tumor metastasis.

Our preliminary data point to the need for clinical testing to establish whether FTC720 therapy might provide an advantage in terms of increased local tumor control to patients with prostate cancer treated with radiotherapy.

Materials and Methods

Cell lines

PC-3, 22Rv1, and DU145 cells were obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, and LNCaP-C4-2B cells were from Viromed; PC-3M are a highly metastatic derivative of PC-3 cells as previously described (30). Cells were cultured between passages 4 and 30 in RPMI 1640 containing 10% fetal bovine serum. Cell lines were routinely verified by morphology and growth curve analysis and were routinely screened for mycoplasma infection (MP0035 Lookout, Sigma). SphK1-overexpressing cell models have been described previously (13). All experiments were conducted in the absence of serum at 50% confluence and then treated as indicated in the figure legends.

Reagents

Culture medium, serum, antibiotics and Syto 13 were obtained from Invitrogen. Escherichia coli diacylglycerol kinase, octyl-D-glucopyranoside, and SKI-II compound were from Merck. γ-[32P]-ATP was purchased from Perkin-Elmer, and silica gel 60 high-performance TLC plates were from VWR. FTC720 was obtained from Novartis. Annexin V–FITC was from BD. All other chemicals were from Sigma Aldrich.

γ-Irradiation was performed using the IBL 637 irradiator (Cis-Bio International) using a Cesium 137 γ-ray source (total activity ~222 TBq) at the dose rate of 1 Gy/minute.

siRNA transfection

SphK1 and S1P1,5 were targeted using siRNA as previously described (13, 31), along with relevant control siRNA. Knockdown was assessed by real-time quantitative reverse transcription-PCR (qRT-PCR) as previously described (16).

Cell viability, flow cytometry, and staining of apoptotic nuclei

Cell viability, flow cytometry, and staining of apoptotic nuclei were measured as previously described using the MTT assay (13), Annexin V–FITC/podophyllotoxin (PI) staining, and Syto13/PI staining (14).

Sphingosine kinase-1 assay and mass measurements of ceramide, sphingosine 1-phosphate, and sphingosine

Sphingosine kinase-1 assay and mass measurements of ceramide, sphingosine 1-phosphate, and sphingosine were performed as described previously (14, 32).

Real-time qRT-PCR

Real-time qRT-PCR was performed as described previously (16).

Caspase-3/7 activity

Caspase-3/7 activity was measured as previously described (14).

Western blot analysis

Western blot analysis was performed as described previously (16).

Animal study

Animal study was performed as previously described (13). Briefly, intraprostatic and s.c. human prostate cancer xenografts were established in NMRI/Nu (nu/nu) 7-week-old male mice by surgical orthotopic implantation or s.c. injection of 1 × 106 PC-3/GFP cells. Three weeks after implantation, mice were randomized into different groups and treated for two weeks with i.p. injections of PBS (control), 2.5 mg/kg/day FTC720, 5 sessions of γ-irradiation (4 Gy) every 3rd day, or γ-irradiation combined with FTC720. Two days after the last treatment, all mice were euthanized with carbon dioxide asphyxiation for sacrifice, and then processed for H&E histology to confirm the nature of the disease or were processed for sphingolipid analyses. Blood counts were determined as previously described (33).

Data representation and statistical analysis

The statistical significance of differences between the means of two groups was evaluated by unpaired two-sided Student’s t test, and the overall significance of multiple groups was evaluated by ANOVA. Calculations were performed using Graphpad Prism Software. Representative images are presented for the experiments carried out with fluorescence.
Results

**Sphingosine analogue FTY720 induces apoptosis in prostate cancer cells by inhibition of SphK1**

FTY720 induces dose-dependent loss of cell viability in metastatic prostate cancer PC-3 cells (Fig. 1A), achieving an IC\textsubscript{50} at \sim 30 hours of exposure at 5 \mu mol/L dose. This loss of cell viability was preceded by an activation of caspase 3 and/or 7 (\sim 2.5 fold at 6 hours; Fig. 1B) and was followed by an increase in apoptotic cells (51 \pm 5\% at 48 hours; Fig. 1C). A similar decrease in cell viability (Fig. 1D) and an increase in apoptosis and caspase-3 activation (not shown) were observed in DU145 metastatic prostate cancer cells, in agreement with previous reports (21, 34).

FTY720 is a sphingosine analogue and was previously shown to inhibit enzymatic activity of recombinant SphK1 (35). Here we report that FTY720 induced a rapid inhibition of SphK1 enzymatic activity in PC-3 and DU145 cells (-28 \pm 5\% and -40 \pm 5\% in PC-3 and DU145 cells, respectively, at 6 hours; Fig. 2). This inhibition was followed by a decrease in intracellular S1P (-18 \pm 6\% and -31 \pm 5\% in PC-3 and DU145 cells, respectively, at 24 hours). Of note, qRT-PCR analysis showed that treatment with FTY720 did not induce significant changes in the expression of the SphK1 gene during first 24 hours (Supplementary Fig. S1).

Overexpression of SphK1 in PC-3 cells rendered them less sensitive to FTY720 (65 \pm 8\% versus 35 \pm 6\% of loss of cell viability in PC-3/NEO versus PC-3/SphK1 cells, respectively; Fig. 2C). Conversely, the silencing S1P1 to S1P5 receptors either individually or altogether did not alter FTY720-induced PC-3 cell death (Supplementary Fig. S2), suggesting a receptor-independent mode of action. Treatment with FTY720 also decreased the levels of intracellular phospho-Akt, which, however, was downstream of FTY720-induced SphK1 downregulation because SphK1 overexpression restored the levels of phospho-Akt in FTY720-treated cells and the SphK inhibitor SKI-II could per se reduce the levels of phospho-Akt (Supplementary Fig. S3). As shown in Fig. 2, FTY720 treatment induced only a late modest increase in intracellular ceramide. Pretreatment of PC-3 cells with fumonisin B1 (inhibitor of \textit{de novo} ceramide synthesis), GW4869 (neutral sphingomyelinase inhibitor), or imipramine (acid sphingomyelinase inhibitor) could not abrogate FTY720-induced apoptosis, suggesting that ceramide accumulation was a consequence of SphK1 inhibition (Supplementary Fig. S4).

**\gamma-Irradiation induces prostate cancer cell death independently of SphK1**

When treated with a single dose of \gamma-irradiation both PC-3 and DU145 cells were sensitive to 10 Gy treatment, achieving a 40\% loss of cell viability at \sim 72 hours and 48 hours for PC-3 and DU145 cells, respectively (Fig. 3A). In both cell lines a further increase in \gamma-irradiation dose to 20 Gy did not lead to a significant increase in cell death (data not shown). On the contrary, both cell lines exhibited a partial resistance when

---

Figure 1. FTY720 induces prostate cancer cell apoptosis. PC-3 (A–C) and DU145 (D) cells were treated with FTY720 at indicated concentrations for the indicated times. A, viability of PC-3 cells was quantified by MTT reduction assay. B, caspase-3/7 activity was measured using luminescent caspase-GLO substrate. C, number of apoptotic cells was quantified by flow cytometry after staining with Annexin V/PI. D, cell viability of DU145 cells. Points, mean of four independent experiments performed in triplicate; bars, SE.
treated with lower doses of γ-irradiation (only ~20% loss after 120-hour treatment with 5 Gy in both cell lines; Fig. 3A).

In contrast to FTY720, treatment of prostate cancer cells with γ-irradiation did not result in SphK1 inhibition. Conversely in DU145 cells, γ-irradiation induced rather an upregulation of SphK1 activity (43 ± 7% and 45 ± 6% by 5 Gy and 10 Gy, respectively, P < 0.05; Fig. 3B), which, however, was not mediated by SphK1 transcription (Fig. 3C).

Figure 2. Sphingosine analogue FTY720 induces in vitro inhibition of SphK1, a decrease in intracellular S1P, and SphK1 overexpression reverts FTY720-induced prostate cancer cell apoptosis. PC-3 (A) and DU145 (B) cells were treated with 5 μmol/L FTY720 for the indicated times and SphK1 activity (top), intracellular S1P (middle), and intracellular ceramide (bottom) were measured as described in Materials and Methods. C, cell viability of PC-3 cells stably overexpressing SphK1 (PC-3/SphK1) or empty vector (PC-3/NEO) as described previously (13), and treated with 5 μmol/L FTY720 for indicated time. Columns, mean of four independent experiments performed in duplicate; points, mean of three independent experiments performed in triplicate; bars, SE. *, P < 0.05; **, P < 0.01; ns, not significant (P > 0.05).

SphK1 inhibition by FTY720 sensitizes prostate cancer cells to γ-irradiation

In line with previous reports showing that SphK1 inhibition by dimethylsphingosine or SKI-II could respectively sensitize prostate cancer cell models to γ-irradiation (3) and chemotherapy (17, 18), here we report that 1 to 5 μmol/L FTY720 successfully sensitized PC-3 and DU145 cells to γ-irradiation (Fig. 4A and B). Fluorescent activated cell sorter analysis...
(Fig. 4C) and fluorescent microscopy (Supplementary Fig. S5) revealed that this radiosensitization was mediated by an induction of apoptosis. Isobologram analysis revealed that in both cell lines FTY720 and γ-irradiation act in synergy (Supplementary Fig. S6). Similarly to FTY720, the SpkK inhibitor SKI-II (Fig. 4D) and SpkK1 siRNA, but not SpkK2 siRNA (Supplementary Fig. S7), sensitized PC-3 and DU145 (not shown) prostate cancer cells to γ-irradiation.

Figure 5 shows that the addition of FTY720 to PC-3 cells subjected to γ-irradiation significantly exacerbated the inhibition of SpkK1 activity (-46.0 ± 5.7% versus 0.2 ± 6.5%, P = 0.0178), comparable with the levels in cells treated with FTY720 alone (-27.5 ± 3.1%; Fig. 5A). Similarly, the addition of FTY720 decreased the levels of intracellular S1P in irradiated PC-3 cells (Fig. 5A). There was no significant difference between the levels of intracellular ceramide in cells subjected to treatments alone or in combination (Fig. 5A).

In DU145, γ-irradiation induced an increase in both SpkK1 activity and intracellular S1P (43.0 ± 6.1% and 36.3 ± 3.6%, respectively), which was completely reversed by the addition of FTY720 (-16.6 ± 4.8% and -19.7 ± 8.2%; Fig. 5B). In contrast to PC-3 cells, combination of FTY720 and γ-irradiation slightly increased intracellular ceramide (Fig. 5B).

Our data show that in contrast to a modest increase in ceramide, 6 hours of treatment with FTY720 induced a significant, transient increase in intracellular sphingosine (Supplementary Fig. S8A). Furthermore, although γ-irradiation did not influence sphingosine production, it acted in synergy with FTY720 (Supplementary Fig. S8A). We then verified the potential of proapoptotic sphingolipids as radiosensitizers. Supplementary Figure S8B shows that both sphingosine and to a smaller extent ceramide could sensitize PC-3 cells to γ-irradiation. Although extracellular ceramide acted as a radiosensitizer (Supplementary Fig. S8B), blocking the generation of intracellular ceramide had no effect on PC-3 cell survival (Supplementary Fig. S9).

Similarly to blocking PC-3 cell apoptosis induced by FTY720 alone (Fig. 2), SpkK1 overexpression abrogated FTY720-induced radiosensitization (Supplementary Fig. S10A). This correlated with a significant decrease in SpkK1 inhibition induced by FTY720 in PC-3 cells overexpressing SpkK1 (Supplementary Fig. S10B). Similarly to SpkK1 overexpression, the addition of extracellular S1P partially blocked PC-3 cell death after treatment with either FTY720 or FTY720 together with γ-irradiation (Supplementary Fig. S11). Although FTY720 alone induced a rapid increase in caspase-3/7 activity (Fig. 1B),
combined treatment with FTY720 and γ-irradiation did not result in a further activation of executioner caspases (Supplementary Fig. S12A). Moreover, addition of a pan-caspase inhibitor, Z-vad.fmk, did not result in a significant protection from FTY720- or combination treatment-induced cell death (Supplementary Fig. S12B). Finally, to verify the universality of FTY720-induced radiosensitization, we treated androgen-sensitive metastatic LNCaP-C4-2B, PC-3M, and nonmetastatic 22Rv1 prostate cancer cells with FTY720 with or without γ-irradiation (Supplementary Fig. S13). Our data show that FTY720 acted as a radiosensitizer in all three cell lines.

FTY720 radiosensitizes human fluorescent PC-3 tumors established in nude mice

Subcutaneous and orthotopic PC-3 tumors were inoculated in nude mice and grown for three weeks. These animals were then treated for two weeks with i.p. injections of PBS (control), 2.5 mg/kg/day FTY720, 5 sessions of γ-irradiation (4 Gy) every 3rd day, or γ-irradiation combined with FTY720. After 5 weeks s.c. tumors in nontreated animals reached 2,190 ± 388 mm³, whereas in animals treated with FTY720 alone their volume was 1,355 ± 149 mm³ (P = 0.0043). γ-Irradiation alone diminished the tumor volume to 870 ± 30 mm³ (P < 0.0001 versus control; P = 0.0007 versus FTY720), whereas combined treatment led to the most significant reduction in tumor volume at 390 ± 70 mm³ (P < 0.0001 versus γ-irradiation; ANOVA; P < 0.0001; Fig. 6A).

Orthotopic PC-3 tumors showed a similar response to the treatments: 469 ± 41 mg, 281 ± 26 mg, 185 ± 13 mg, and 34 ± 12 mg in mice treated with control, FTY720, γ-irradiation, or combined treatment respectively (P < 0.0001, ANOVA; P < 0.0001, t-test γ-irradiation versus combined treatment; Fig. 6B).

Figure 6C shows that although γ-irradiation alone did not significantly affect the levels of tumor SphK1 activity (100 ± 5.0 versus 89.5 ± 7.9, not significant; in animals receiving control or γ-irradiation, respectively), treatment with FTY720 or a combination of FTY720 with γ-irradiation significantly reduced SphK1 activity (76.3 ± 6.6 versus 56.2 ± 9.4 in animals treated with FTY720 or a combination of FTY720 with γ-irradiation, respectively). Levels of tumor S1P were lower in animals treated with combination therapy than in animals receiving γ-irradiation alone. The difference between intracellular ceramide levels in all four groups did not reach significance (Fig. 6C).

The effect of combination therapy on primary tumor growth was paralleled by a significant reduction of distant metastasis (adrenal, liver, and lungs, excluding aortic lymph nodes as being a primary site for prostate cancer metastasis; positive in all animals) with 63% (5 of 8) of animals free of distant metastases (compared with 100% in both untreated...
and FTY-treated groups, and 25% in irradiated animals, with 2 of 8 metastases-free; Fig. 6D).

Fluorescent imaging revealed that FTY720 alone did not affect the number of secondary tumors (3.33 ± 0.44 versus 3.14 ± 0.54 metastases/mouse in control and FTY720 groups, respectively, P not significant), whereas γ-irradiation significantly reduced the number of distant metastases (1.43 ± 0.29 metastases/mouse). Combination treatment further reduced the number of distant tumors (0.55 ± 0.23 metastases/mouse, P = 0.0366 in comparison with γ-irradiation alone; Fig. 6D).

**FTY720 and γ-irradiation reduce WBC counts in nude mice**

In nude mice a single 2.5 mg/kg dose of FTY720 induced a rapid reduction of leukocyte blood counts which within 3 days normalized to control levels (Supplementary Fig. S14A). To identify the impact of prolonged FTY720 treatment on blood cell counts, blood was analyzed at the time of sacrifice (two days after the last treatment with FTY720). Mice treated with FTY720 alone had a moderate ∼30% reduction in total circulating leukocytes and lymphocytes, and no changes were observed in peripheral macrophages and granulocytes (Supplementary Fig. S14B), as reported previously (36, 37).

**Discussion**

In this current study we provide compelling evidence that FTY720 is a SphK1 inhibitor and a potent radiosensitizer of human prostate cancer both *in vitro* and *in vivo*.

Several lines of evidence suggest that FTY720 has an anti-proliferative potential in prostate cancer cells. FTY720 was previously reported to induce apoptosis in DU145 cells (21, 34). Here we show for the first time that FTY720 is a strong inducer of apoptosis in hormone-refractory, metastatic prostate cancer PC-3 cells. FTY720-induced apoptosis in PC-3 cells was dose dependent and was preceded by significant upregulation of caspase 3 and 7 activity (Fig. 1).

FTY720 has been previously reported to inhibit SphK1 *in situ* (35). In our study we show for the first time that FTY720 has a capacity to inhibit SphK1 enzymatic activity *in vitro* (Fig. 2) and that this inhibition is not related to a reduction in SphK1 expression (Supplementary Fig. S1A). SphK1 inhibition seems to be a crucial step in FTY720-induced prostate cancer apoptosis, because SphK1 overexpression exerts a cytoprotective effect (Fig. 2). This cytoprotection is partial, however, which indicates the existence of parallel, SphK1-independent mechanisms of
FTY720-induced prostate cancer apoptosis. We verified the involvement of several previously suggested mechanisms of FTY720-induced cancer cell apoptosis in our system. In contrast to La Montagne et al. (24), knockdown of S1P receptors showed that FTY720-induced cell death was S1P receptor independent, suggesting an intracellular mode of action (Supplementary Fig. S2). Similarly to Azuma et al. (26), we found that FTY720 induced a downregulation of

---

Figure 6. FTY720 radiosensitizes human fluorescent PC-3 tumors established in nude mice. Three weeks after tumor implantation, mice were randomized into four groups and subjected to daily i.p. injections of 2.5 mg/kg FTY720 (total dose 35 mg/kg), 4 Gy radiotherapy every 3 days (total dose 20 Gy), a combination of these treatments, or a sham treatment by i.p. injections. A, volume of s.c. tumor measured with a caliper at weekly intervals. B, tumor mass of excised primary green fluorescent protein (GFP)-labeled tumor (top) and representative fluorescent primary prostate tumors at the time of autopsy from groups treated with sham (Cont), FTY720, γ-irradiation (Irr), and a combination of FTY720 and γ-irradiation (bottom). Red arrows, primary orthotopic GFP tumors. C, SphK1 activity (top), and S1P (middle) and ceramide (bottom) levels were measured in tissue extracts obtained from primary tumors. D, number of distant metastases (lungs, liver, pancreas, mesenteric and kidney) per animal. Columns, points, means of 8 animals; bars, SE. *, P < 0.05; **, P < 0.01; ***; P < 0.001; ns, not significant (P > 0.05).
Akt phosphorylation (Supplementary Fig. S3). This effect was SphK1 dependent, however, because it could be mimicked by SphK1 inhibition and restored by SphK1 overexpression. Finally, our data show that FTY720-mediated ceramide accumulation was not responsible for FTY720-induced apoptosis because pretreatment of prostate cancer cells with inhibitors of sphingomyelinasises and de novo ceramide synthesis pathway did not abrogate FTY720-induced apoptosis (Supplementary Fig. S4). Overall, our data suggest a SphK1-mediated S1PR-independent mechanism of prostate cancer cell apoptosis induced by FTY720.

Sphingolipids have previously been shown to play a role in prostate cancer radioresistance. Radioresistant prostate cancer cell lines are deficient in the generation of pro-apoptotic ceramide and sphingosine, and the addition or increased production of these lipids is radiosensitizing (3, 38, 39). In contrast to completely radioresistant, androgen-sensitive LNCaP prostate cancer cells, both DU145 and PC-3 hormone-refractory metastatic prostate cancer cells respond to γ-irradiation in a dose-dependent manner. With this in mind, one of the major aims of our study was to investigate possible therapeutic dose intensification. In contrast to several DNA-damaging therapies that were previously shown to downregulate SphK1 activity (13, 40, 41), here we report that in both PC-3 and DU145 metastatic prostate cancer cell lines γ-irradiation–induced apoptosis was not associated with SphK1 inhibition (Fig. 3) or an increase in intracellular ceramide (Fig. 5). Interestingly in DU145 cells, irradiation even induced a slight activation of SphK1 (but not through transcription), an effect observed in several cancer cell lines treated with DNA-damaging agents (13, 42). We therefore conclude that in metastatic prostate cancer cells γ-irradiation does not regulate the SphK1/S1P pathway, which suggests that its external manipulation may provide benefit in terms of dose intensification.

We have shown that SK1 inhibition leads to a promotion of the effects of cytotoxic chemotherapy on cell lines (13, 14, 16). Although metastatic prostate cancer cells are partially responsive to γ-irradiation, sustained SphK1 activity may provide an “escape from apoptosis” for these cells. We hypothesized that SphK1 inhibition may, in addition to its effects on chemotherapy, serve as potential radiosensitizer. Here we show for the first time that FTY720 can sensitize hormone-refractory metastatic human prostate cancer tumors established in nude mice. Our in vivo data show that treatment with FTY720 alone decreased the size of both s.c. and orthotopic tumors (Fig. 6). Furthermore, cotreatment with FTY720 resulted in a further reduction in both orthotopic and s.c. tumors treated with γ-irradiation. In our models the efficacy of FTY720 was correlated to a decrease in tumor SphK1 activity and S1P levels (Fig. 6C).

At the selected dose (2.5 mg/kg/day), treatment with FTY720 alone had only a moderate effect on primary tumor growth (Fig. 6). In contrast to previous data showing the ability of FTY720 to block cell invasion in prostate cancer three-dimensional cell cultures (28), in our model treatment with FTY720 alone did not influence the number of distant metastases. Surprisingly, γ-irradiation alone led to a significant reduction in the number of distant metastases, which was further enhanced by cotreatment with FTY720, suggesting a synergistic mechanism of action between FTY720 and γ-irradiation.

In accordance with previous studies, prolonged treatment with 2.5 mg/kg/day FTY720 led to a moderate lymphopenia (Supplementary Fig. S4B). The major reported complication of FTY720 is a transient decrease in the heart rate due to a “first dose” effect, and no toxic effects had been observed in healthy volunteers treated for 7 consecutive days with 5 mg/day FTY720 (44, 45). At the used dose (2.5 mg/kg/day), we did not observe any toxicity or gross abnormalities (like weight loss or i.p. inflammation) in animals treated with FTY720. It is worth noting that until recently no clinically tested SphK1 inhibitors were available. Conversely, recent data from phase III trials show clinical safety and significant potential of oral FTY720 (fingolimod) in multiple sclerosis patients (19, 20).
In conclusion, here we show for the first time that FTY720 induces prostate cancer apoptosis and radiosensitization through SphK1 inhibition. Our data draw attention to the potential of FTY720 as an adjuvant treatment for local tumor control in prostate cancer patients treated with radical radiotherapy.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

The Royal Society (grant P24841 to D. Pchejetski), The Prostate Cancer Charity (grant 110630 to D. Pchejetski), Institut National du Cancer (O. Cuvillier), Centre National de la Recherche Scientifique (O. Cuvillier) Institut National de la Santé et de la Recherche Médicale and Ministère de la Santé (Interface Program, O. Cuvillier), and Association pour la Recherche sur le Cancer (O. Cuvillier).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 04/26/2010; revised 07/22/2010; accepted 08/09/2010; published OnlineFirst 10/19/2010.

References


FTY720 (Fingolimod) Sensitizes Prostate Cancer Cells to Radiotherapy by Inhibition of Sphingosine Kinase-1

Dmitri Pchejetski, Torsten Bohler, Leyre Brizuela, et al.

Cancer Res Published OnlineFirst October 19, 2010.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-10-1388

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2010/10/18/0008-5472.CAN-10-1388.DC1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.